Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial
Patel KT, Stevens MC, Dunlap A, Gallagher A, O’Malley S, DeMartini K, Potenza MN, Krystal JH, Pearlson GD. Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial. Neuropsychopharmacology 2021, 47: 840-846. PMID: 34475522, PMCID: PMC8882177, DOI: 10.1038/s41386-021-01157-5.Peer-Reviewed Original ResearchConceptsProtein tyrosine kinasesSrc regulationSrc familyProtein kinaseTyrosine kinaseFyn kinaseSrc inhibitorSrc/FynDependent pathwayKinaseNMDAR upregulationNMDAR functionNMDA receptorsRegulationSaracatinibGluN2B subunitGlutamate receptorsFynInhibitorsReceptorsSubunitsN-methyl-D-aspartate (NMDA) glutamate receptorsPrevious evidence